Trial Profile
Phase II open label study of ultra-selection of patients by genotyping technology for next-generation scheme in FOLFIRI + panitumumab patients with stage IV colorectal cancer resistant to irinotecan without detectable mutations using highly sensitive techniques for the detection of mutations in genes KRAS, PIK3CA, BRAF and NRAS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms ULTRA
- 12 Sep 2017 Results assessing circulating tumour DNA to track tumour heterogeneity (n=16) presented at the 42nd European Society for Medical Oncology Congress
- 22 Feb 2017 Status changed from active, no longer recruiting to completed.
- 22 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2016.